FOLH1 and cancer: Second, when cancer-control outcomes of [177Lu]Lu-PSMA mCRPC patients aged >75 years at time of metastases were compared, comparable median PFS and OS outcomes were observed and no difference were found after further additional adjustment in Cox regression models.